Generic Version of Fusilev Launched by Mylan

Article

Mylan has launched a generic version of Spectrum Pharmaceuticals' levoleucovorin calcium injections.

Mylan has launched a generic version of Spectrum Pharmaceuticals’ levoleucovorin calcium injections (Fusilev).

The treatment is indicated for rescue use after high-dose methotrexate therapy in osteosarcoma. It can also be used to lower toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists, according to Mylan.

The new generic version, following the FDA’s approval of Mylan’s abbreviated new drug application (ANDA), comes in 10 mg, 175 mg, and 250 mg single-use vials.

Mylan currently has 259 ANDAs pending FDA approval. These ANDAs are valued at $98.5 billion, according to IMS Health.

US sales of the Fusilev injections brought in $200 million for the fiscal year ending on June 30, 2015, according to IMS Health.

Sandoz launched its own generic version of Fusilev in May 2015.

Related Videos
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
BillionPhotos.com - stock.adobe.com
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim - stock.adobe.com
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Image credit: Fabio Balbi | stock.adobe.com
Image credit: Melita - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.